Matrix Global Advisors
  • Home
  • About
  • News
  • Reports
  • Contact
  • Follow
  • Follow
Humira Rivals Set to Try to Drive Down Cost of Blockbuster Drug

Humira Rivals Set to Try to Drive Down Cost of Blockbuster Drug

Jan 31, 2023 | Interviews

“Given the long-term success of Humira, which can cost patients up to $84,000 a year, initial uptake of the biosimilars may be limited, said Alex Brill, founder and CEO of economic policy consulting firm Matrix Global Advisors.”

2022 Midterms: How a Democratic or GOP Congress May Impact Your Federal Taxes

2022 Midterms: How a Democratic or GOP Congress May Impact Your Federal Taxes

Oct 26, 2022 | Interviews

“If Republicans take control of Congress in this fall’s election, protecting previously passed policies will be among the party’s top priority, said Alex Brill, a senior fellow at the American Enterprise Institute for Public Policy Research, a conservative think tank based in Washington, D.C. “

‘The Price of Business’: Discussing State Taxation of Student Loan Forgiveness

‘The Price of Business’: Discussing State Taxation of Student Loan Forgiveness

Oct 12, 2022 | Interviews

On October 12, Alex Brill joined Kevin Price on ‘The Price of Business’ to discuss the state tax implications of President Biden’s student loan relief plan. 

Revisiting the Tax Treatment of Pass-Through Businesses: A Panel Discussion

Revisiting the Tax Treatment of Pass-Through Businesses: A Panel Discussion

Oct 3, 2022 | Events

On October 3, AEI’s Alex Brill and Kyle Pomerleau hosted a panel of experts to discuss the tax treatment of pass-through businesses and opportunities for reform.

‘The Price of Business’: Discussing State Taxation of Student Loan Forgiveness

‘The Price of Business’: Discussing Today’s Political and Economic Environment

Jun 8, 2022 | Interviews

On June 8, Alex Brill joined Kevin Price on ‘The Price of Business’ discussing today’s political and economic environment. Brill shared his sentiments on the economic outlook.

« Older Entries
Next Entries »
  • Analysis (54)
  • Books (3)
  • Commentary (15)
  • Events (21)
  • Interviews (60)
  • News (55)
  • Op-Eds (101)
  • Press Releases (4)
  • Testimony (21)
  • FDA Continues to Expedite Biosimilar Development
    FDA Continues to Expedite Biosimilar DevelopmentMarch 18, 2026
  • Government’s Drug Negotiation Program
    Diminishing Returns from the Government’s Drug Negotiation ProgramJanuary 29, 2026
  • ACA Tax Credit Extension Matter
    Would Senate Passage of an ACA Tax Credit Extension Matter?January 14, 2026
  • PBMs Pass Through Rebates
    MGA Brief Examines State and Federal PBM MandatesDecember 1, 2025
  • FDA Moves to Facilitate Biosimilar Development
    FDA Moves to Facilitate Biosimilar DevelopmentOctober 30, 2025
  • How Pharmaceutical Tariffs Will Affect US Health Care Costs
    How Pharmaceutical Tariffs Will Affect US Health Care CostsSeptember 26, 2025
  • Quantifying the economic impact of healthcare distributors
    MGA Releases New Report Quantifying the Economic Impact of Healthcare DistributorsSeptember 17, 2025
  • Unsung Hero of the OBBBA
    The Unsung Hero of the OBBBA: Permanent ExpensingAugust 20, 2025
  • Alex Brill Interviewed by Biosimilars Review & Report
    Alex Brill Interviewed by Biosimilars Review & ReportAugust 6, 2025
  • Medicare Price Negotiations and Drug Competition
    MGA Releases New White Paper on Medicare Price Negotiations and Drug CompetitionJuly 14, 2025
© Copyright 2022 Matrix Global Advisors | Design By DreamBig Creative
MGA
  • Home
  • About
  • News
  • Reports
  • Contact